BIIB061
/ Biogen
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
June 01, 2023
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
(clinicaltrials.gov)
- P2 | N=0 | Withdrawn | Sponsor: Biogen | N=300 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • CNS Disorders • Multiple Sclerosis
November 25, 2020
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
(clinicaltrials.gov)
- P2; N=300; Not yet recruiting; Sponsor: Biogen; Trial completion date: Jul 2023 ➔ Sep 2024; Trial primary completion date: Jul 2023 ➔ Sep 2024
Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis
September 08, 2020
"Remyielination!!!?? #BIIB061 #opicinumab @biogen #elezanumab @AbbVieUS #CNMAu8 @CleneNano #Inception5 @Roche @genentech"
(@ALFONFX)
July 07, 2020
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
(clinicaltrials.gov)
- P2; N=300; Not yet recruiting; Sponsor: Biogen; Trial completion date: Oct 2022 ➔ Jul 2023; Initiation date: Jun 2020 ➔ Sep 2020; Trial primary completion date: Oct 2022 ➔ Jul 2023
Clinical • Trial completion date • Trial initiation date • Trial primary completion date • CNS Disorders • Multiple Sclerosis
January 22, 2020
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS)
(clinicaltrials.gov)
- P2; N=300; Not yet recruiting; Sponsor: Biogen; Initiation date: Dec 2019 ➔ Jun 2020
Clinical • Trial initiation date
October 04, 2019
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS)
(clinicaltrials.gov)
- P2; N=300; Not yet recruiting; Sponsor: Biogen; Trial primary completion date: May 2022 ➔ Oct 2022
Clinical • Trial primary completion date
September 06, 2019
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) in Relapsing Multiple Sclerosis (RMS)
(clinicaltrials.gov)
- P2; N=300; Not yet recruiting; Sponsor: Biogen
Clinical • New P2 trial
1 to 7
Of
7
Go to page
1